BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia. It is also developing AGI-134, an immuno-oncology agent, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of skin lesions. The company has collaboration agreement with MSD for the cancer immunotherapy field; MD Anderson Cancer Center to investigate the combination of Motixafortide with KEYTRUDA (pembrolizumab) in pancreatic cancer; and licensing arrangement with Perrigo Company plc for over-the-counter sale of BL-5010. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.
Last 10 Buy Signals
Date |
Signal |
@ |
VKTX | Apr 24 - 12:10 | $64.86 |
MDB | Apr 24 - 12:10 | $362.02 |
DEXEUSD | Apr 24 - 12:09 | 13.56 |
GFUSX | Apr 24 - 11:59 | 256.92 |
LEUSX | Apr 24 - 11:59 | 176.08 |
CHKP | Apr 24 - 12:07 | $160.32 |
RGEN | Apr 24 - 12:04 | $166.54 |
XAUTUSD | Apr 24 - 12:04 | $2 322.64 |
DXCM | Apr 24 - 12:03 | $136.39 |
AXSM | Apr 24 - 12:02 | $71.24 |